Supplementary Figure 2 from Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling

PDF - 163K, A, Establishment of stable integrinβ1-overexpressing cell lines (PC9/ITG2 and PC9/ITG11) or control cDNA transfected cell line (PC9/Mock) from PC9 cells by transfection with integrinβ1 cDNA. B, The effect of integrinβ1 overexpression on erlotinib sensitivity. Transfectants were treated with erlotinib for 3 days, and the IC50 values (μM) for erlotinib were 0.04 (PC9/Mock), 0.09 (PC9/ITG2), and 0.10 (PC9/ITG11). C, Western blots showing the expression and phosphorylation of EGFR, integrinβ1, Akt, and Erk1/2 following exposure to erlotinib for 5 hr.